Immunic CEO discusses Phase 2 multiple sclerosis study success

Immunic Inc. (NASDAQ:IMUX) CEO Dr. Daniel Vitt highlighted positive Phase 2 data for vidofludimus calcium in multiple sclerosis, demonstrating a low rate of confirmed disability worsening and significant reduction in inflammatory lesions in relapsing-remitting MS (EMPhASIS trial), alongside strong long-term safety and patient retention. Additionally, the CALLIPER Phase 2 study in progressive MS showed a 24-32% reduction in disability worsening. These results corroborate the drug's neuroprotective potential and have led to two ongoing Phase 3 ENSURE studies for relapsing MS, with data expected by late next year, positioning Immunic for potential regulatory approval by addressing a critical unmet need for slowing disability progression.

Analysis

Immunic Inc. (IMUX) has presented compelling long-term data from its Phase 2 EMPhASIS trial for vidofludimus calcium in relapsing-remitting multiple sclerosis (RRMS), highlighting a low rate of confirmed disability worsening (CDW) in patients treated for up to five and a half years. This result reinforces the neuroprotective potential initially suggested in the trial, which had already met its primary endpoint by demonstrating a 76-78% reduction in inflammatory lesions. The drug's safety and tolerability profile appears robust, underscored by an exceptionally high patient retention rate, with 182 of the 254 patients who entered the open-label extension still on treatment. This positive RRMS data is further corroborated by the impressive results from the separate Phase 2 CALLIPER study in progressive MS, which showed a 24% reduction in disability worsening (32% in the PPMS subgroup). The company has now fully enrolled two pivotal Phase 3 ENSURE studies (1,122 patients), with a data readout expected by the end of next year, which will serve as the primary catalyst for a potential regulatory filing. The consistent evidence across multiple trials supports the CEO's assertion that vidofludimus calcium addresses the critical unmet need for treatments that slow disability progression, potentially positioning it as a highly differentiated therapy.

Key Decisions for Investors

• Investors should view the upcoming Phase 3 ENSURE trial data, expected by the end of next year, as the primary catalyst for IMUX, as positive results are required for regulatory submission and would significantly de-risk the company's lead asset.
• Consider the drug's dual anti-inflammatory and neuroprotective profile as a key competitive advantage; the consistent data on slowing disability progression across different MS populations could support a strong market position if Phase 3 trials are successful.
• The excellent long-term safety and patient tolerability data is a significant value driver for a chronic therapy and should be factored into valuation models, as it may facilitate physician adoption and patient adherence post-approval.